{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.012","value":"86.24"},{"groupId":"OG001","spread":"16.848","value":"81.49"}]}],"title":"Physical Impact (n=278,140)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.920","value":"85.65"},{"groupId":"OG001","spread":"18.233","value":"78.65"}]}],"title":"Psychological Impact (n=277,141)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.117","value":"83.77"},{"groupId":"OG001","spread":"19.230","value":"57.38"}]}],"title":"Impact on ADLs (n=266,140)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.428","value":"82.32"},{"groupId":"OG001","spread":"17.473","value":"60.14"}]}],"title":"Convenience (n=279,143)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.051","value":"89.58"},{"groupId":"OG001","spread":"18.232","value":"77.39"}]}],"title":"Satisfaction (n=282,141)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"284"},{"groupId":"OG001","value":"144"}],"units":"Participants"}],"description":"The RASQ is a 20-item questionnaire that measures five domains related to the impact of treatment administration. These include physical impact, psychological impact, impact on activities of daily living (ADLs), convenience, and satisfaction. Each domain is scored on a scale of 0 to 100, with higher scores indicative of more positive feelings toward therapy. The score for each domain was averaged among all participants.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with previously untreated, CD20-positive DLBCL received up to 8 cycles of rituximab in combination with CHOP. Treatment was given on Day 1 of each cycle, and the cycle length (14 or 21 days) was decided by the study center. For Cycle 1, rituximab was administered at a dose of 375 mg/m\\^2 via IV infusion; subsequent doses were given as 1400 mg via SC injection. Tumor response was assessed after 4 cycles according to criteria published by Cheson et al (1999), which are presented in Outcome Measure 1. The duration of CHOP therapy could be reduced from 8 to 6 cycles for those who achieved CR or CRu after 4 cycles, but all participants received a full 8 cycles of rituximab.","id":"OG000","title":"Rituximab SC"},{"description":"Participants with previously untreated, CD20-positive DLBCL received up to 8 cycles of rituximab in combination with CHOP. Treatment was given on Day 1 of each cycle, and the cycle length (14 or 21 days) was decided by the study center. For all cycles, rituximab was administered at a dose of 375 mg/m\\^2 via IV infusion. Tumor response was assessed after 4 cycles according to criteria published by Cheson et al (1999), which are presented in Outcome Measure 1. The duration of CHOP therapy could be reduced from 8 to 6 cycles for those who achieved CR or CRu after 4 cycles, but all participants received a full 8 cycles of rituximab.","id":"OG001","title":"Rituximab IV"}],"paramType":"MEAN","populationDescription":"ITT Population (RASQ Subpopulation): All participants who completed the RASQ at Cycles 3 and 7; n = number of participants in the analysis for the specified domain.","reportingStatus":"POSTED","timeFrame":"At Cycle 7 (each cycle was 14 or 21 days)","title":"Rituximab Administration Satisfaction Questionnaire (RASQ) Domain Scores","type":"SECONDARY","unitOfMeasure":"units on a scale"}